Xeomin®

In summer of 2011, the FDA approved XEOMIN® (incobotulinumtoxinA) for the temporary improvement in the appearance of moderate to severe glabellar lines, or frown lines between the eyebrows, in adult patients.

Similar to Botox® or Dysport™, XEOMIN injections can temporarily improve the appearance of frown lines.

Produced by Merz Aesthetics, the makers of Radiesse, XEOMIN is scheduled to be available to most physicians in the spring of 2012. Due its elite status, MDLSV was given access to start treatment in November, 2011.